Westfield Capital Reduces McKesson Holdings

Hedge fund sells 1,279 shares of pharmaceutical distributor in Q3

Published on Feb. 27, 2026

Got story updates? Submit your updates here. ›

Westfield Capital Management Co. LP reduced its holdings in shares of McKesson Corporation (NYSE:MCK) by 16.0% in the third quarter, according to the company's recent 13F filing with the Securities and Exchange Commission (SEC). The firm now owns 6,732 shares of the company's stock, valued at $5,201,000 at the end of the reporting period.

Why it matters

McKesson is one of the largest pharmaceutical distributors in the United States, playing a critical role in the healthcare supply chain. Changes in institutional ownership of the company's stock can provide insights into market sentiment and potential shifts in the industry.

The details

Westfield Capital Management, a Boston-based hedge fund, sold 1,279 shares of McKesson in the third quarter, reducing its total position by 16%. The firm now holds 6,732 shares of the company, worth over $5.2 million. McKesson's stock has seen strong performance in recent quarters, with the company reporting better-than-expected earnings and revenue growth.

  • Westfield Capital Management reduced its McKesson holdings in the third quarter of 2026.

The players

Westfield Capital Management Co. LP

A Boston-based hedge fund that reduced its holdings in McKesson Corporation in the third quarter of 2026.

McKesson Corporation

A global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Westfield Capital's McKesson holdings suggests a potential shift in market sentiment around the pharmaceutical distribution industry, though the company remains a major player in the space. Investors will likely continue to monitor institutional ownership changes and financial performance for insights into the broader healthcare supply chain.